European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.
The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.
Lundbeck, una farmacéutica global con sede en Dinamarca, ha acordado comprar Longboard Pharmaceuticals, con sede en La Jolla, ...
Lundbeck, a global drugmaker based in Denmark, has agreed to buy La Jolla-based Longboard Pharmaceuticals for $2.6 billion to ...
Fintel reports that on October 15, 2024, HC Wainwright & Co. downgraded their outlook for Longboard Pharmaceuticals (NasdaqGM ...
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Longboard Pharmaceuticals (LBPH – Research ...
Lundbeck’s acquisition of Longboard Pharmaceuticals is meant to bolster its neuro-rare disease franchise, the drugmaker ...
Lundbeck, a biopharmaceutical company based in Denmark, has announced the acquisition of Longboard Pharmaceuticals in a ...
Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion. Read more on ...
Just in the first half of 2024, over $1.7 billion was committed to autoimmune disease research. The influx is driven largely ...
On Monday, Longboard Pharmaceuticals Inc (LBPH) stock saw a modest uptick, ending the day at $58.99 which represents a slight increase of $20.09 or 51.65% from the prior close of $38.9. The stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback